FierceBiotech ٢٠ أبريل ٢٠٢٦ AACR: Endeavoring to go global, Zai Lab offers reality check on China’s biotech ascent
FierceBiotech ٢٠ أبريل ٢٠٢٦ Novo readies SCD drug from $1.1B Forma buyout for approval push after phase 3 win
FierceBiotech ٢٠ أبريل ٢٠٢٦ Lilly picks up another in vivo CAR-T company with Kelonia buyout worth up to $7B
FierceBiotech ٢٠ أبريل ٢٠٢٦ Biogen inks $850M biobucks deal with TJ Biopharma for China rights to late-stage immune antibody
FierceBiotech ٢٠ أبريل ٢٠٢٦ Agenus focuses on survival data as 0% response rate triggers primary miss
FierceBiotech ٢٠ أبريل ٢٠٢٦ Odyssey charts fresh voyage to public markets after abandoning IPO plans last year
FierceBiotech ٢٠ أبريل ٢٠٢٦ AstraZeneca’s faith in IL-33 inhibitor continues to pay off with latest phase 3 COPD win
FierceBiotech ٢٠ أبريل ٢٠٢٦ How WuXi AppTec’s Integrated Platform Is Helping Therapies Move Faster from Discovery to Patients
FierceBiotech ٢٠ أبريل ٢٠٢٦ FDA celebrates progress to end animal testing but experts warn there’s still a long way to go
FierceBiotech ٢٠ أبريل ٢٠٢٦ AACR: Former Genentech leader engineers startup with vision for ‘smart’ cancer drugs
FierceBiotech ١٨ أبريل ٢٠٢٦ AACR: FDA vet Pazdur bemoans state of agency, warns of political influence and ‘sense of anxiety’
FierceBiotech ١٧ أبريل ٢٠٢٦ UCB pays $650M+ for Neurona, marking 'strategic expansion' into regenerative medicine
FierceBiotech ١٧ أبريل ٢٠٢٦ Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 plans